1. Home
  2. KBDC vs ABCL Comparison

KBDC vs ABCL Comparison

Compare KBDC & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KBDC
  • ABCL
  • Stock Information
  • Founded
  • KBDC 2021
  • ABCL 2012
  • Country
  • KBDC United States
  • ABCL Canada
  • Employees
  • KBDC N/A
  • ABCL N/A
  • Industry
  • KBDC
  • ABCL Biotechnology: Pharmaceutical Preparations
  • Sector
  • KBDC
  • ABCL Health Care
  • Exchange
  • KBDC Nasdaq
  • ABCL Nasdaq
  • Market Cap
  • KBDC 1.1B
  • ABCL 1.1B
  • IPO Year
  • KBDC N/A
  • ABCL 2020
  • Fundamental
  • Price
  • KBDC $13.58
  • ABCL $5.90
  • Analyst Decision
  • KBDC Buy
  • ABCL Strong Buy
  • Analyst Count
  • KBDC 4
  • ABCL 5
  • Target Price
  • KBDC $16.50
  • ABCL $8.00
  • AVG Volume (30 Days)
  • KBDC 419.8K
  • ABCL 5.5M
  • Earning Date
  • KBDC 11-12-2025
  • ABCL 11-06-2025
  • Dividend Yield
  • KBDC 14.00%
  • ABCL N/A
  • EPS Growth
  • KBDC N/A
  • ABCL N/A
  • EPS
  • KBDC N/A
  • ABCL N/A
  • Revenue
  • KBDC N/A
  • ABCL $32,875,999.00
  • Revenue This Year
  • KBDC $193.84
  • ABCL $16.99
  • Revenue Next Year
  • KBDC $7.09
  • ABCL $63.73
  • P/E Ratio
  • KBDC N/A
  • ABCL N/A
  • Revenue Growth
  • KBDC N/A
  • ABCL N/A
  • 52 Week Low
  • KBDC $13.06
  • ABCL $1.89
  • 52 Week High
  • KBDC $17.99
  • ABCL $6.41
  • Technical
  • Relative Strength Index (RSI)
  • KBDC 32.06
  • ABCL 71.87
  • Support Level
  • KBDC $13.08
  • ABCL $4.51
  • Resistance Level
  • KBDC $13.97
  • ABCL $5.11
  • Average True Range (ATR)
  • KBDC 0.28
  • ABCL 0.36
  • MACD
  • KBDC -0.05
  • ABCL 0.14
  • Stochastic Oscillator
  • KBDC 35.37
  • ABCL 75.24

About KBDC Kayne Anderson BDC Inc. Common Stock

Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Share on Social Networks: